FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its ...
USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September ...
Feb 10 (Reuters) - Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results